Yourgene Health PLC Issue of Share Options (5578Q)

TIDMYGEN

RNS Number : 5578Q

Yourgene Health PLC

19 June 2020

Yourgene Health plc

("Yourgene" or the "Company")

Issue of Share Options

Manchester, UK - 19 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the issuance of 470,000 share options under its existing share option scheme to two employees.

The new share options have performance conditions based on EPS growth over the next three years, in line with the Company's share option scheme rules and previously issued share options. The exercise price of these options is 18 pence. The total number of share options now in issue is 61,379,232, representing 9.8% of the as-enlarged share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 
Yourgene Health plc                                                  Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                              investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                 Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
 
Stifel Nicolaus Europe Limited (Sole                                 Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor       Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                           Mob: 07980 541 893 / Mob: 07584 391 
                                                                                          303

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEUKOVRRKUNAAR

(END) Dow Jones Newswires

June 19, 2020 11:44 ET (15:44 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024